SLS: Gunggung dhuwit awis saben saham SELLAS Life Sciences Group

SELLAS Life Sciences develops vaccines based on GPS technology to combat the WT1 protein. On GURU.Markets, the cash per share metric exhibits volatility driven by massive R&D platform expenditures and the binary risks associated with a narrow drug portfolio. The current value of 0.67 captures the metric level, reflecting the company's real-time liquidity dynamics while awaiting regulatory decisions.
Rincian metrik komprehensif lan analitis SELLAS Life Sciences Group, Inc. (SLS)

This metric determines the volume of available liquidity per common share, allowing for an assessment of financial stability and capital headroom. By analyzing the trend of liquid assets per share, an investor can track the burn rate of reserves for SELLAS Life Sciences (SLS) clinical trials, which, under a scalable vaccine production model, will not require capital expenditures for plant construction.